Urothelial Carcinoma Bladder

Oncology
1
Pipeline Programs
2
Companies
14
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
SasanlimabPhase 2Monoclonal Antibody5 trials
Active Trials
NCT07206225Recruiting294Est. Jan 2033
NCT06870487Active Not Recruiting6Est. Feb 2026
NCT06974734Active Not Recruiting9Est. Apr 2026
+2 more trials
KARL STORZ Endoscopy
KARL STORZ EndoscopyCA - El Segundo
1 program
En bloc transurethral resection of bladder tumorN/A1 trial
Active Trials
NCT04712201RecruitingEst. Apr 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
PfizerSasanlimab
PfizerSasanlimab
PfizerSasanlimab
PfizerSasanlimab
PfizerSasanlimab
PfizerSasanlimab
PfizerSasanlimab
PfizerSasanlimab
PfizerSasanlimab
PfizerSasanlimab
PfizerSasanlimab
PfizerSasanlimab
PfizerSasanlimab
KARL STORZ EndoscopyEn bloc transurethral resection of bladder tumor

Clinical Trials (14)

Total enrollment: 1,624 patients across 14 trials

NCT04165317PfizerSasanlimab

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

Start: Dec 2019Est. completion: Dec 20261,068 patients
Phase 3Active Not Recruiting
NCT05241340PfizerSasanlimab

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer

Start: Feb 2022Est. completion: Apr 202733 patients
Phase 2Active Not Recruiting
NCT07206225PfizerSasanlimab

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Start: Nov 2025Est. completion: Jan 2033294 patients
Phase 1Recruiting
NCT06870487PfizerSasanlimab

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

Start: May 2025Est. completion: Feb 20266 patients
Phase 1Active Not Recruiting
NCT06974734PfizerSasanlimab

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

Start: May 2025Est. completion: Apr 20269 patients
Phase 1Active Not Recruiting
NCT06704724PfizerSasanlimab

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Start: Dec 2024Est. completion: Mar 202930 patients
Phase 1Active Not Recruiting
NCT06580938PfizerSasanlimab

A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

Start: Nov 2024Est. completion: Jul 20254 patients
Phase 1Terminated
NCT06448364PfizerSasanlimab

A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination

Start: May 2024Est. completion: Aug 20244 patients
Phase 1Terminated
NCT06285097PfizerSasanlimab

A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors

Start: Feb 2024Est. completion: Feb 20259 patients
Phase 1Terminated
NCT05259397PfizerSasanlimab

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Start: Mar 2022Est. completion: Sep 20220
Phase 1Withdrawn
NCT05233436PfizerSasanlimab

PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

Start: Feb 2022Est. completion: Oct 202321 patients
Phase 1Terminated
NCT05061537PfizerSasanlimab

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Start: Oct 2021Est. completion: Oct 202213 patients
Phase 1Terminated
NCT04254107PfizerSasanlimab

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Start: May 2020Est. completion: Dec 2023133 patients
Phase 1Terminated
NCT04712201KARL STORZ EndoscopyEn bloc transurethral resection of bladder tumor

En Bloc Bladder Tumor Resection: Prospective Randomized Study

Start: Apr 2018Est. completion: Apr 2026
N/ARecruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 1,624 patients
2 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)